Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP: ESALY )

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
What This Label Expansion Means for Merck
The Keytruda-Lenvima combo was recently approved for its second oncology indication. 
Via The Motley Fool
Exposures Product Safety
White House Dismisses Janet Woodcock As Permanent FDA Commissioner Candidate: Bloomberg
The Biden Administration has ruled out the nomination of acting FDA commissioner Janet Woodcock as permanent head of the agency, Bloomberg reported citing people... 
Via Benzinga
Exposures Product Safety
Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei's
Eisai Co Ltd (OTC: ESALY) and its U.S. partner Biogen Inc's (NASDAQ: BIIB) Alzheimer's treatment Aduhelm (aducanumab) will be used by more than 300... 
Via Benzinga
The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs
The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC:... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
News Overload
Today US markets managed a rally despite misses in both the growth and employment data. 
Via Talk Markets
Full News Day
The US greatly increased its exports of liquified natural gas in the first half-year, to 9.6 billion cubic feet per day, a rise of 42% from a year earlier. 
Via Talk Markets
Topics Energy
Exposures Fossil Fuels
Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients
An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) ... 
Via Benzinga
Containment Plan
Today the US decided to cut China risks. 
Via Talk Markets
Joblessness Surprise
Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices. 
Via Talk Markets
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
Exposures Product Safety
“Claw-Back” day
The rally was just as irrational as the selloff. 
Via Talk Markets
Delta Defeats Bulls
Stocks tended to crash without rhyme or reason. 
Via Talk Markets
Weak Week
Friday tried a recovery because retail sales data for June were strong, particularly in dining out, although in the end, the weak tech side cut the optimism. 
Via Talk Markets
Biogen's Alzheimer's Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News
Acting FDA Commissioner Janet Woodcock pushed back against media questions about the agency's controversial approval of Alzheimer's treatment, Aduhelm developed by ... 
Via Benzinga
Exposures Product Safety
Dialing For Stocks
Thanks to Fed Chairman Powell, markets brushed off worrying about inflation today. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients
Biogen Inc. (NASDAQ:BIIB) shares are lower after the compa... 
Via Benzinga
Exposures Product Safety
People Needed
If qualified people are not looking for work, they will have to be lured to do so with higher wages. 
Via Talk Markets
Exposures Labor
End Of June
Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Summer Friday
The stock market tried for another record after yesterday's late blowout over the infrastructure deal. 
Via Talk Markets
Crazy Thursday
Today the US stock market went ballistic probably because of a higher joblessness level than expected. 
Via Talk Markets
Wednesday Is A Normal Day
Meme stocks Gamestop and Torchlight Energy both did share sales to cash in on their share price rises. 
Via Talk Markets
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
The First Day Of Summer And Prime Day
The bull is back in business today. 
Via Talk Markets
3 More Reasons Biogen's Alzheimer's Drug Will Underperform Wall Street Expectations
Beyond its lofty price tag, there are other impediments to big sales of aducanamab that the market largely ignored this week. 
Via The Motley Fool
Did This Company Just Win Big Because of Biogen?
Alzheimer's disease patients who take Aduhelm will need a lot of diagnostic scans, too. Imaging leader RadNet stands to benefit. 
Via The Motley Fool
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.